Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.

What this Trial Is About

Researchers are investigating the role of metabolomics in lung cancer by analyzing tissue and peripheral blood samples at key treatment stages. The study aims to identify metabolic changes that could serve as biomarkers to distinguish between benign and malignant lung nodules, predict treatment effectiveness, and assess long-term outcomes. This observational research is conducted by The First Affiliated Hospital of Guangzhou Medical University to enhance personalized lung cancer care. The study involves monitoring serum metabolites using tissue and blood samples collected at critical points such as initial lung nodule screening, after surgery to evaluate treatment results, and during ongoing therapy to assess its impact. These metabolic profiles are analyzed to uncover differences linked to disease progression and response to treatment, helping to understand underlying mechanisms and develop better diagnostic and prognostic tools. Participants will provide tissue and blood samples at these defined times, allowing researchers to track metabolic alterations over several years. The primary outcome measure is the area under the curve over 3 years, with secondary outcomes including identification of differentially expressed metabolites during this period. This long-term follow-up aims to provide insights into how metabolomics can improve diagnosis, prognosis, and therapy monitoring in lung cancer patients.

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.